Piper Sandler Maintains Overweight on Gilead Sciences, Raises Price Target to $112
Piper Sandler analyst Do Kim maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $111 to $112.
Why Gilead Sciences Stock Is Trading Higher After Hours
Gilead Sciences Inc (NASDAQ: GILD) shares are trading higher in Thursday's after-hours session after the company reported
February PDUFA Catalysts Biotech Investors Must Know: Sanofi’s Bleeding Disorder Drug, Regeneron’s Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year.
Kite and Arcellx Close Agreement To Co-Develop And Co-Commercialize Late-Stage Clinical CART-ddBCMA In Multiple Myeloma
Kite, a Gilead Company (NASDAQ:GILD), and Arcellx, Inc. (NASDAQ:ACLX), today announced the closing of the companies' previously announced global strategic collaboration to co-develop and co-commercialize
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.
If You Invested $100 In This Stock 15 Years Ago, You Would Have $400 Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.47% on an annualized basis…
Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $80
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowers the price target from $81 to $80.
16 Analysts Have This to Say About Gilead Sciences
Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Piper Sandler Maintains Overweight on Gilead Sciences, Raises Price Target to $111
Piper Sandler analyst Do Kim maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $104 to $111.
Wells Fargo Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $90
Wells Fargo analyst Mohit Bansal maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $75 to $90.